Competing risk analysis on outcome after hepatic resection of hepatocellular carcinoma in cirrhotic patients

Table 2 Cumulative incidence of death from tumour recurrence and from liver failure resulting from competing risk analysis

	Death from tumour recurrence			Death from liver failure
	1-year (%)	3-year (%)	5-year (%)	1-year (%)	3-year (%)	5-year (%)
Age (yr)		P = 0.915			P = 0.267
< 67	3.8 (0.9)	19.9 (2.2)	28.1 (2.6)	4.5 (1.0)	6.2 (1.2)	7.8 (1.4)
≥ 67	3.2 (0.8)	14.7 (1.9)	28.1 (2.8)	4.3 (1.0)	6.7 (1.3)	10.5 (1.8)
Gender		P = 0.738			P = 0.287
Male	3.6 (0.7)	17.7 (1.7)	27.7 (2.1)	4.2 (0.8)	6.6 (1.0)	8.5 (1.2)
Female	3.4 (1.4)	15.4 (2.9)	28.2 (4.1)	5.0 (1.6)	7.2 (1.9)	11.1 (2.8)
Hepatitis C infection		P = 0.838			P = 0.032
Positive	3.7 (0.8)	15.9 (1.8)	27.4 (2.4)	5.3 (1.0)	7.5 (1.2)	10.9 (1.6)
Negative	3.2 (1.0)	19.3 (2.5)	28.3 (3.1)	2.8 (0.9)	4.7 (1.2)	5.9 (1.5)
Portal hypertension1		P = 0.515			P = 0.029
Absent	3.6 (0.8)	17.6 (1.8)	27.2 (2.3)	3.3 (0.8)	5.1 (1.0)	6.9 (1.2)
Present	3.3 (1.0)	16.5 (2.3)	28.8 (3.2)	6.2 (1.4)	8.9 (1.7)	12.9 (2.2)
MELD score		P = 0.760			P = 0.001
< 9	4.2 (1.0)	16.7 (2.0)	27.7 (2.8)	1.9 (0.7)	3.3 (0.9)	5.2 (1.3)
9-10	2.5 (0.9)	17.7 (2.5)	27.8 (3.2)	4.7 (1.2)	6.0 (1.4)	10.2 (2.1)
> 10	3.6 (1.6)	17.3 (3.6)	27.7 (4.7)	11.0 (2.7)	16.6 (3.2)	17.9 (3.4)
UNOS T-stage		P = 0.002			P = 0.597
T1	1.0 (0.0)	7.6 (0.2)	14.5 (0.7)	1.2 (1.0)	3.2 (2.3)	10.6 (4.6)
T2	3.0 (0.7)	15.4 (1.8)	25.0 (2.4)	4.1 (0.9)	6.7 (1.2)	8.7 (1.4)
T3-T4a	5.8 (1.5)	26.3 (3.0)	34.6 (3.6)	6.0 (1.5)	7.8 (1.7)	9.3 (2.0)
Hepatectomy extension		P = 0.042			P = 0.052
Wedge/segmentectomy	3.2 (0.7)	15.2 (1.6)	26.7 (2.3)	3.0 (0.7)	5.5 (1.0)	8.7 (1.4)
Two or more segments	4.4 (1.4)	22.3 (2.9)	30.7 (3.5)	8.1 (1.8)	9.0 (1.9)	10.3 (2.1)

Standard errors are reported in parentheses.

¹Defined as presence of oesophageal varices and/or platelet count < 100000/mL. MELD: Model for End-stage Liver Disease; UNOS: United Network for Organ Sharing.